Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

https://www.globenewswire.com/news-release/2024/02/26/2834807/0/en/Zealand-Pharma-announces-Boehringer-Ingelheim-survodutide-Phase-2-trial-shows-83-of-adults-treated-achieved-groundbreaking-results-in-liver-disease-due-to-MASH-with-significant-imp.html

company announcement